Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain - PubMed (original) (raw)
Affiliations
- PMID: 2786562
Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain
N J Riachi et al. J Pharmacol Exp Ther. 1989 Jun.
Abstract
We studied blood-to-brain entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridinium (MPP+) and butanol in anesthetized rats using the indicator-fractionation method with right atrial bolus injection. Minimal amounts of MPP+, which has low octanol/water partition coefficient, crossed the blood-brain barrier. MPTP and butanol, both of which have high octanol/water partition coefficients, were almost completely extracted by all regions of the brain on the first pass. The main difference between the MPTP and butanol tracers is that butanol rapidly left the brain with an exponential rate constant of 1.24 min-1, whereas MPTP was avidly retained by the brain with a washout rate constant of 0.10 min-1 (mean values for the four brain regions that we studied). Early retention of MPTP by the brain was not due to its rapid metabolism by monoamine oxidase because pargyline pretreatment did not affect this rate constant. However, 30 min after [3H]MPTP injection, brain retention of the 3H tracer was reduced significantly by pargyline treatment, and the ratio of brain MPTP/MPP+ was increased markedly.
Similar articles
- Acute peripheral catecholaminergic changes in rat after MPTP and MPP+ treatment.
Ambrosio S, Mahy N. Ambrosio S, et al. Rev Esp Fisiol. 1989 Jun;45(2):157-61. Rev Esp Fisiol. 1989. PMID: 2570448 - A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
Corsini GU, Pintus S, Bocchetta A, Piccardi MP, Del Zompo M. Corsini GU, et al. J Pharmacol Exp Ther. 1986 Aug;238(2):648-52. J Pharmacol Exp Ther. 1986. PMID: 3488394 - The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P, Marsden CD. Jenner P, et al. J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review. - MPTP toxicity and the "biochemical" blood-brain barrier.
Harik SI. Harik SI. NIDA Res Monogr. 1992;120:43-53. NIDA Res Monogr. 1992. PMID: 1501691 Review. No abstract available.
Cited by
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Parkinson's disease and enhanced inflammatory response.
Stojkovska I, Wagner BM, Morrison BE. Stojkovska I, et al. Exp Biol Med (Maywood). 2015 Nov;240(11):1387-95. doi: 10.1177/1535370215576313. Epub 2015 Mar 13. Exp Biol Med (Maywood). 2015. PMID: 25769314 Free PMC article. Review. - The MPTP Story.
Langston JW. Langston JW. J Parkinsons Dis. 2017;7(s1):S11-S19. doi: 10.3233/JPD-179006. J Parkinsons Dis. 2017. PMID: 28282815 Free PMC article. Review. - MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Przedborski S, Tieu K, Perier C, Vila M. Przedborski S, et al. J Bioenerg Biomembr. 2004 Aug;36(4):375-9. doi: 10.1023/B:JOBB.0000041771.66775.d5. J Bioenerg Biomembr. 2004. PMID: 15377875 Review. - Positive Tetrahydrocurcumin-Associated Brain-Related Metabolomic Implications.
Josifovska S, Panov S, Hadzi-Petrushev N, Mitrokhin V, Kamkin A, Stojchevski R, Avtanski D, Mladenov M. Josifovska S, et al. Molecules. 2023 Apr 26;28(9):3734. doi: 10.3390/molecules28093734. Molecules. 2023. PMID: 37175144 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous